Back to search

University of Minnesota

Harnessing Natural Killer Cells for Improved Therapeutic Potential

Abstract

dc:description.abstract

Cellular immunotherapy provides durable control for infected and transformed cells. However, current Natural Killer (NK) cell therapy products are limited by effector persistence. To this end, three strategies to improve the efficacy of NK cell-based therapies are discussed. Killer immunoglobulin-like receptors (KIR) are developed during maturation of NK cells. It showed that KIR develops primarily between CD56brightCD94high and CD56dimCD94high stages. Major demethylation activities were observed during the development of KIR at its proximal promoter region. Ascorbic acid showed to facilitate the development of KIR in collaboration with Ten-eleven translocation (TET) enzymes. NK cells with adaptive immunological properties persist and expand in response to cytomegalovirus (CMV) infection. The levels of intracellular metabolites were analyzed and showed that adaptive NK cells have relatively higher levels of metabolites associated with glycolysis, purine, and pyrimidine metabolism. This supports the notion that adaptive NK cells have upregulated metabolic profiles, and have capacity to expand upon reactivation of CMV which is similar to the characteristics of memory T cells. To address challenges associated with inconsistencies of the manufactured product, and treatment cost, we developed a triple gene-edited induced pluripotent stem cell (iPSC) platform for broad patient-based adoptive cell therapy. First edit is to introduce non-cleavable CD16 which prevents reduced efficacy by antibody-dependent cellular cytotoxicity (ADCC). Second edit allows iPSC-derived NK cells, termed iNK, to persist without supplementation of exogenous IL-15 by introducing IL-15 receptor fusion. The last edit was to avoid daratumumab-induced fratricide by knocking out CD38 on the surface of the iNK cells. These engineered iNK cells persisted in vivo without supplementation of exogenous cytokine and could be combined with daratumumab for enhanced treatment of multiple myeloma. The gene-edited iNK cells exhibited metabolic features and gene expression profiles similar to those of adaptive NK cells which has broad off-the-shelf potential for the treatment of advanced cancer.

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Kim, Hansol

Subjects

dc:subject × 6

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*
Dc Identifier Citation
Kim, Hansol. (2021). Harnessing Natural Killer Cells for Improved Therapeutic Potential. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/225009.

Chain of custody

source
Harvested from
University of Minnesota
Base URL
conservancy.umn.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Kim, Hansol. Harnessing Natural Killer Cells for Improved Therapeutic Potential. 2021. https://hdl.handle.net/11299/225009